Amylyx Pharmaceuticals

The work to support the global #neurodegenerative disease community never stops. Subscribe for the latest updates from Amylyx at www.amylyx.com.

We recently partnered with the Margaret Fuller Neighborhood House to create snack kits that will help families in the Greater Boston area. Thank you to the Amylyx team members who participated in this community give-back activity and who contribute to our culture of caring each and every day.

This coming Monday, our Chief Medical Officer, Camille Bedrosian, MD, will join the Longwood Healthcare Leaders Boston CEO Meeting to discuss innovation in clinical trials, including the importance of patient-centricity and how we can continue to advance meaningful progress. We’re looking forward to the outputs of this important collaboration with industry leaders and are eager to contribute to conversations that are shaping the next era in healthcare innovation. Thank you, Longwood Healthcare Leaders, for bringing us together!   For more information check out: https://lnkd.in/eehfZ2xB

We’re excited to attend the Northeast ALS Consortium (NEALS) annual meeting next week, which brings together researchers, clinicians, industry leaders, and individuals living with ALS to discuss the latest advancements in research and treatment. See below for more details.

Today, we announced positive topline data from our open-label, Phase 2 HELIOS clinical trial in 12 adults with Wolfram syndrome. The study showed improvement in pancreatic function, as measured by C-peptide response after 24 weeks of treatment with our investigational therapy, in contrast to the progression expected in this disease. Similar overall improvements or stabilization were observed across all secondary endpoints, including measures of glycemic control and vision.   We thank the Wolfram syndrome community for their continued collaboration and support.   Learn more: https://bit.ly/3Nyno5K   #WS #WolframSyndrome

We will be sharing topline data from our Phase 2 HELIOS study in #Wolframsyndrome at the International Society for Pediatric and Adolescent Diabetes (ISPAD)’s 50th Annual Conference next week and in a webcast hosted by the Amylyx team and Dr. Fumihiko Urano. More details in our press release: https://bit.ly/3NrZSHO

Post-bariatric hypoglycemia (PBH) is a condition affecting people who have undergone bariatric surgery. ~160,000 people are currently living with symptomatic PBH in the U.S. The perspectives below illustrate the serious, debilitating symptoms and consequences that current management approaches are not sufficiently addressing. Read more:

Our September Anchor Week brought #TeamAmylyx together for interactive sessions, building new connections, and some fun too! Without a doubt, the highlight was kicking off a new Beyond the Diagnosis series with special guests Raquel and Stephanie Gebel (The Snow Foundation) and Dr. Sarah Gladstone.

Earlier this week, Amylyx’ Chief Medical Officer Camille Bedrosian, MD, spoke on a Fierce Biotech Summit panel discussing what the industry’s challenges and important advances have meant for neuroscience innovation. Thanks for having us, Fierce! 

Today is Wolfram Syndrome Global Awareness Day! We’re continually inspired by the #Wolframsyndrome community. A heartfelt thanks to Raquel for sharing what living with Wolfram syndrome and advances in research mean to her in the video below. Learn more about her family’s work and advocacy via The Snow Foundation at https://lnkd.in/eV4P7_b5.  #WSGAD